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Background/aim: Next generation sequencing provides new information about the molecular pathogenesis of cancer. We used a
targeted NGS-based multiple gene panel comprising prostate cancer (PCa) predisposing genes to assess the prevalence of germline
mutations in PCa patients.
Material and methods: In a cohort of twenty-one PCa patients with a family history of cancer, a targeted multigene panel consisting
of 39 genes associated with hereditary cancer was created and analyzed using the next generation sequencing method. The novel and
pathogenic mutations detected were confirmed by Sanger sequencing method. Thereafter, the data obtained were evaluated using
different genomic variant classifiers and databases.
Results: With an incidence of less than 5% in different populations (MAF<0.05); a total of 81 variants were identified, including 41
missense, 16 synonymous, 3 splice-site, 11 intronic, 5 in-del and 5 novels. According to the ACMG criteria, 5 (6.2%) of these variants
are pathogenic/likely pathogenic; 5 (6.2%) of them were classified as novel variants. In addition, variants having very low-frequency and
unknown clinical significance (VUS) in the databases were detected.
Conclusion: The findings we obtained from this study contributed to the understanding the genetic pathogenesis of PCa, determining
the frequency of mutations in the population, and revealing the genotype-phenotype correlations. Additionally, we demonstrated that
using multigene panel-based genetic tests rather than single-gene tests in germline mutation screening in hereditary PCa will be more
beneficial in terms of genetic counseling.
Key words: Next generation sequencing, bioinformatics, prostate cancer, databases, germline mutations

1. Introduction
The genetic etiology of prostate cancer (PCa) is complex
and poorly understood. Furthermore, there are multiple
predisposing factors that can also affect severity,
progression, and the outcome of PCa [1]. Genetic changes
that are known as copy number variations, point mutations,
small insertions or deletions, structural rearrangements,
and chromosomal aberrations are generally involved in
carcinogenesis, which can be in germline DNA or tumor
genome [2].
Germline (i.e. inherited) mutations that predispose to
hereditary cancers have become the focus of many studies;
therefore, they have the potential to predict both incidence
and prognosis. In addition, these variations have important
implications in areas such as staging, screening, treatment,
genetic counselling, and cascade testing of family members
and, hence, can serve as therapeutic targets [3]. However,

diverse ethnic population, geographic heterogeneity, the
presence of rare variants, and incomplete family histories
create limitations to use these variations for this purpose.
Therefore, it is important to overcome these limitations as
hereditary risk of PCa has been associated with a higher
Gleason score, metastases at diagnosis, and poor prognosis
[4, 5]. According to the NCCN guidelines (Prostate
Cancer, Version 2.2019), positive family history increases
the risk of developing this disease and according to studies
approximately 11% of patients with PCa, and at least one
additional primary cancer carries germline mutation
associated with increased cancer risk. Consequently, the
relevant guideline recommends that all patients with
PCa should be carefully examined in terms of their own
information and family histories [6].
With the advancement of next generation sequencing
(NGS) technologies, simultaneous sequencing of cancer
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susceptibility genes has been achieved and has become a
more effective genetic testing strategy compared to single
gene testing [7]. These recent advances in NGS technology
have, therefore, both enabled us to better understand the
biology of prostate tumors as well as and supported an
understanding of the genetic basis of the clinical variability
of the disease and an orientation towards a personalized
treatment paradigm [3, 7].
In this study, germline mutation screening application
was performed with multi-panel tests. With multi-panel
tests, germline mutation screening are well-established
diagnostic tools to identify the origin of cancer clusters
in a family. They also provide early diagnosis and
implementation of the most appropriate preventive
measures. Patients with PCa who also have a familial
history of cancer were included in this study and DNA
repair genes as well as genes associated with PCa in GWAS
studies were sequenced with targeted next generation
sequencing method, which aimed to correlate with the
connection of the detected mutation, single nucleotide
polymorphism (SNP), small deletions and insertions
with the help of databases. In addition, it is also aimed to
identify new gene variants, determine pathogenic, clinical
significance of unknown (VUS), novel variants frequencies,
and establish genotype-phenotype correlations.
2. Material and methods
2.1. Patient data
The study was initiated with the decision of Süleyman
Demirel University Faculty of Medicine Clinical Research
Ethics Committee (Date 11.03.2019, No:92). Written
informed consent was obtained from all the patients.
Twenty-one patients, between the ages of 45 and 75
(mean age 64.7 ± 7.9 years) who were diagnosed with PCa
and had a family history of cancer applied to Süleyman
Demirel University Faculty of Medicine, Urology
policlinic, were included in the study. Volunteers meeting
the study criteria in patients who applied to the urology
policlinic were randomly selected and recruited. Patients
with malignancies other than PCa were excluded from
the study. Prostate-specific antigen (PSA) levels (mean
37.9 ± 41.4) were evaluated in the serum of the patients.
Histopathological grading was done according to the
Gleason score (GS) grading methods.
2.2. Extraction of genomic DNA
Genomic DNA (gDNA) was extracted from peripheral
blood using a MagPurix Blood DNA Extraction Kit. DNA
was isolated from a 200-μL blood sample using Zinexts
MagPurix system (Zinexts Life Science Corp., New Taipei
City, Taiwan) according to the manufacturer’s protocol.
2.2. Multi-gene panel testing using targeted NGS
DNA libraries were generated by the target exon-capture
method. Paired-end sequencing was performed on the
Illumina MiSeq NGS System (Illumina Inc, San Diego,
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CA, USA) using the MiSeq Reagent Nano Kit v2 (500
cycles) (Catalog No: MS-103-1003, Illumina Inc., San
Diego, CA, USA). In this study, all the coding exons
±25 bp from each direction of 39 PCa associated genes
(AKT1, APC, AR, ATM, BARD1, BRCA1, BRCA2,
BRIP1, CDKN2A, CHEK2, EHBP1, ELAC2, EPCAM,
EPHB2, FANCA, FGFR4, GREM1, HNF1B, HOXB13,
IGF2, ITGA6, MLH1, MSH2, MSH6, MSMB, MSR1,
MUTYH, NBN, PALB2, PLXNB1, PMS2, POLD1, POLE,
RAD51C, RAD51D, RNASEL, STK11, TP53, WT1) were
sequenced by using hybridization-based targeted genomic
sequencing (Celemics, Inc., South Korea). On average,
29% of the annotations obtained are within the target area
(annotation on Target-CDS±25 bp) and 71% of them are
outside the target area (annotations off target). In the study,
the ratio of the target region covered above the depth of
20X was 98.30%, and the ratio of the target region covered
at a depth of 50X and above was 88.55%.
2.3. Sequencing data analysis, filtering criteria
Our bioinformatics analysis involves 5 steps: fastq
quality control, sequence alignment (Burrows-Wheeler
Alignment
(BWA)-MEM
Tool),
post-alignment
processing (MarkDuplicates), variant calling (Freebayes),
and downstream analyses. As the first step of downstream
analysis, we filtered variants according to the population
allele frequency and discarded the variants that were
seen more than 5% frequency in any given databases. In
addition to the population databases, the synonymous
variants were not included in the variant results. Various
bioinformatics tools were applied for variant calling,
depending on the current germline mutation calling
analysis pipelines. The read quality of the high throughput
sequence data obtained as FASTQ raw data was assessed
using the FASTQC (Babraham Bioinformatics) program.
The data obtained were aligned to the human reference
genome GRCh37.p12 with the BWA-MEM tool, which
works with the local alignment algorithm. Low-quality
data (reads) were trimmed with the Trimmomatic tool and
duplicated reads were filtered with the MarKDuplicates
tool since hybridization-based kits were used in the study.
As a result of the study, reads between 150K and 500K were
obtained per sample. On average, for each sample, 10% of
the reads could not be aligned. In our study: Clinvar dated
2021-04-18 and dbSNP dated 2020-04-21 (v154) were
used. The Het/Hom ratio was used in the quality control
phase. In the study of Guo et al., it is stated that Het/
Hom ratio should be 2.0 in WGS studies based on HardyWeinberg equilibrium [8]. The Het/Hom ratio of our study
is 2.2. The coverage requirements for reporting were ≥20
unique reads (20X) for each base. In our study, the average
read depth per base was found to be 218. The detected
variants were verified with the IGV (integrative genomics
viewer) program.
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2.4. Evaluation of the pathogenicity of the variants
As a continuation of the downstream analysis, the
detected genomic variants were annotated with the help
of several databases and platforms. GnomAD, ExAC, 1000
Genomes, ESP6500 databases were used for the population
frequencies of the variants we detected. In order to examine
the effects of the variants, ClinVar, Varsome, and Franklin
were used to evaluate the pathogenicity of the variants
according to American College of Medical Genetics and
Genomics (ACMG) classification. The detected genomic
variants were annotated with the help of several databases
and platforms.
2.5. Confirmation analysis
All variants detected as novel, pathogenic (P) and likely
pathogenic (LP) obtained after the NGS study were
confirmed by the Sanger 3500 Series Genetic Analyzers
sequencing method (Applied Biosystem, ThermoFisher,
Scientific, USA). DNA samples of 50 ng from the patients
carrying these variants were amplified by PCR method
with the targeted primers. Amplification products were
paired-end sequenced with BigDye Terminator v3.1, in
accordance with the manufacturer’s instructions. The
data obtained were analyzed with SeqScape v3.0 and
Sequencing Analysis v6.0 (ThermoFisher, Scientific, USA)
software using the GRCh37/hg19 reference genome.
Primer sequences are available under request.
3. Results
3.1. Identification of candidate variants
In 21 PCa samples examined in our study, the incidence
of the variants in different populations was below 5%; a

total of 81 variants were identified, including 41 missense,
16 synonym, 3 splice-site, 11 intronic, 5 in-del and 5 novel
mutations. Percentage distribution of all the variants
we found by genes are; APC (7%), AR (5%), ATM (2%),
BARD1 (1%), BRCA1 (1%), BRCA2 (9%), BRIP1 (4%),
CDKN2A (1%), CHEK2 (4%), EHBP1 (5%), ELAC2 (2%),
EPHB2 (2%), FANCA (7%), FGFR4 (4%), ITGA6 (4%),
MSH2 (1%), MSH6 (5%), MSMB (1%), MSR1 (1%), MUYH
(2%), NBN (1%), PLXNB1 (7%), POLE (5%), POLD1 (4%),
PMS2 (2%), RAD51C (2%), RNASEL (1%), STK11 (1%),
TP53 (2%), WT1 (2%) (Figure). The most variant was
found in the BRCA2 (9%) gene, followed by APC (7%),
FANCA (7%) and PLXNB1 (7%). Heterozygous variants
c.497C>G in APC, heterozygous variants c.3887C>A in
APC, heterozygous variants c.722-10T>C in CHEK2,
heterozygous variants c.1638A>C in FANCA, heterozygous
variants c.182+11_182+15delAGACCinsGGACT in
ITGA6 have not been previously defined in population
databases, and it was evaluated as a novel mutation
according to the ACMG criteria. Additionally, VUS and
variants with very low frequency were detected in the
databases.
Variants were not found in the AKT1, CDKN2A,
EPCAM, GREM1, HNF1B, HOXB13, IGF2, MLH1,
PALB2, RAD51D, and RNASEL genes. All variants (except
for the AR gene homozygous c.1174C>T variant observed
in one patient) were found to be heterozygous. The Human
Genome Variation Society (HGVS) names, gnomAD,
ExAC, ESp6500, 1000 Genome frequencies, and other
features of all the filtered variants, which are missense and
novel, were summarized in Table 1.

Figure Percentage distribution of variants detected in PCa patients.
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Table 1. Minor allel frequency and classification of variants identified in patients with PCa.
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Table 1. (Continued).
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3.2. Variant classification and genotype-phenotype
correlations
Variants were evaluated according to the recommendations
of ACMG Standards and Guidelines. Germline mutations
were detected in 18 out of 21 samples and mutations that
meet the criteria were not found in 3 samples at all. Of
the missense variants we detected classification was as the
following: According to the VarSome database, 27 (60%)
were B/LB, 13 (28.9%) were VUS, 5 were (11.1%) P/LP;
according to the Franklin database, 18 (40%) were B/LB,
26 were (57.8%) VUS, 1 was (2.2%) P/LP; according to
the ClinVar database, 21 (46.7%) were B/LB, 7 (15.6%)
were VUS, 2 (4.4%) were P/LP, and 15 (33.3%) were NA.
Pathogenic/likely pathogenic (P/LP) variants correspond
to 6.2% of all variants meeting the criteria and these variants
were seen in 28.5% of patients. According to VarSome,
Franklin, and ClinVar databases; BRIP1 (c.139C>G), AR
(c.1174C>T and c.237_239delGCA), TP53 (c.654C>T),
MUTYH (c.2T>C) variants were classified as P/LP. Other
variants were classified as benign, likely benign, and VUS.
First-degree relatives of patients with P/LP had a history
of cancer. Patients with P/LP and novel variants (mean age
59.78 ± 5.3) were diagnosed at a younger age than patients
without these variants (mean age 68.4 ± 7.7). Of the patients
carrying germline positive variant, 44.4% were metastatic
prostate cancer, 5.6% clinical stage T2a, 5.6% clinical stage
T2b, 16.7% clinical stage T2c, and 27.8% clinical stage T3a.
P/LP variant was detected in 3 (14.3%) of 7 men with PCa
with Gleason score of 6, and in 3 (21.4%) of 14 men with
PCa with Gleason score of 7 and above. Serum PSA mean
of patients with novel mutation was 19.57 ± 19.47, while
the mean of serum PSA of patients with P/LP variant was
14.33 ± 17.66. Patients with high PSA values and metastatic
cancer had at least 3 related germline mutations. Details of
the missense and novel variants and clinical characteristics
of patients with these variants are given in Table 2.
4. Discussion
This study is the first research that determines the
spectrum of genes related to the disease in patients with
PCa who have a familial history of cancer. In our study,
we performed target capture sequencing by using a custom
designed multigene panel to estimate the frequency of
pathogenic and novel germline variant carriers in patients
with PCa. It was found that 28% of patients had deleterious
cancer susceptibility gene mutations. Additionally, 5 novel
variants were identified that had never been previously
described in the literature or reference databases. The
tumor stage was not different between patients with
and without deleterious mutations. However, the age at
diagnosis was lower in patients with a positive deleterious
mutation. It could also be said that individuals carrying
variants in DNA repair genes are at risk of PCa, since
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both the most frequently mutated genes and genes with
pathogenic/novel variants are associated with DNA repair
functions.
Studies have stated that the probability of PCa
occurring as a result of variants inherited from families
is 37.5%. Thus, identifying a pathogenic variant in a PCa
patient can provide many benefits [9]. In the literature,
mostly BRCA genes have been taken into consideration
in germline mutation screening studies in PCa. Although
it was not found a P/LP variant in BRCA genes in this
study, the most frequently mutated gene was BRCA2 (9%).
Due to the link between different cancer syndromes and
common clinical outcomes, a wide range of candidate
genes including BRCA genes was created in this study.
Therefore, expanded NGS gene panels would be greatly
useful not only for the clinical management of patients but
also for identifying high-risk asymptomatic individuals in
subsequent generations and relatives [10].
In this study, sequence analysis of 39 genes associated
with PCa obtained a diagnostic yield of 28%. As a result,
most pathogenic mutations were detected in the AR gene.
The homozygous AR c.1174C>T pathogenic variant was
found in a patient at diagnosis age of 52, at clinical stage T3a.
Pathogenic variant of AR c.237_239delGCA was detected
in 2 patients. The clinical stage of both patients was T3a,
and the age of diagnosis was 55 and 62. This variant was
previously detected in the group with testicular cancer,
but no significant difference was found compared to the
control group [11]. It was known that the variants in the
AR gene which plays a role in the development of prostate
tissue were associated with an increased risk of PCa [12].
Furthermore, it had been shown that the AR gene regulates
the transcriptional mechanism of DNA repair genes [13].
The study in which the AR gene was sequenced in PCa in
the literature was limited. It was reported these germline
variants were detected in PCa patients for the first time in
Turkey. The results in this study supported the necessity of
including the AR gene in clinical genetic testing of PCa.
One P/LP germline mutation was detected in each of
the BRIP1, TP53, MUTYH genes according to ClinVar and
Varsome. The patient with BRIP1 c.139C>G pathogenic
variant was 62 years of age at diagnosis, the clinical stage
metastasis, and Gleason score was 8 (4+4). This variant
had not been previously reported in PCa. Moyer et al. [14]
found ATPase deficiency and helicase activity deficiency in
the protein of this variant in a functional study performed
in breast cancer. In the literature, missense mutations in the
TP53 gene had been associated with the development of
cancer, and it was suggested that PCa sensitivity develops
in families carrying these variants [4]. The diagnosis age
of patient with pathogenic TP53 c.604C>T variant was 65
and clinical stage metastasis and gelason score was 7 (4+3).
This variant had been previously reported in various
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cancers and had been classified as P/VUS [15]. Although
the connection of the MUTYH gene with the risk of PCa
was not clear, it was added to the test panel in this study
as the protein product of the gene plays a role in repairing
mismatches that occur in DNA replication. The population
frequency of the missense MUTYH c.2T>C variant had
not been previously reported. Leongamornlert et al.
[16] reported that the MUTYH gene c.940C>T variant
detected in a PCa patient was inherited in families and
was associated with disease severity. In accordance with
the literature, the clinical stage of the patients who carried
the c.2T>C variant was T3a, and the age of diagnosis was
58. Considering the clinical data of patients with these P/
LP variants, it could be said that it caused more aggressive
progress. Although functional losses in these genes
are associated with cancer, larger studies are needed to
confirm this.
In this study, 5 novel variants in the APC, CHEK2,
FANCA, and ITGA6 genes were identified. These variants
were missense, intronic, and indel variants. These variants,
which were not found in the ClinVar database, were
classified as VUS in the VarSome and Franklin databases.
Through silico tools such as PolyPhen-2 and SIFT, the
pathogenicity of these variants was predicted as damaging.
There was no information in the literature regarding
the variants of the APC gene which were c.497C>G and
c.3887C>A. Nicolosi et al. [4] reported the frequency
of APC gene variants to be 4.5% among those carrying
germline mutations in their study of 3607 PCa patients.
They also argued that the connection of APC with PCa was
not clear [4]. In this study, the fact that the APC gene (7%)
was the most frequently mutated gene and the Gleason
score of patients carrying these novel variants were 8 (4+4)
may explain the sensitivity of PCa. Sufficient evidence
could not be found for the pathogenicity classification of
the intronic CHEK2 c.722_10T>C variant, which was not
previously reported in databases. The Gleason score of the
patient carrying this variant was 7 (4+3), and the age of
diagnosis was 64. Paulo et al. [15] reported that variants
in the CHEK2 gene would cause activation impairment
due to loss of DNA damage response and phosphorylation
deficiency. In the literature, loss of function in the FANCA
protein involved in homologous recombination repair
had been associated with PCa [17]. The missense FANCA
c.1638A>C variant detected in this study had not been
reported in databases before. Therefore, sufficient data
could not be reached to evaluate its pathogenicity. However,
it was striking that the age of diagnosis of the patient
carrying this variant was 48 years. The study conducted
by Mamidi et al. [18] showed the effect of various somatic
and germline mutations on the aggressiveness of PCa and
stated that some germline mutations in the ITGA6 gene

had an effect on aggressiveness. The indel variant ITGA6
c.182+11_182+15delAGACCinsGGACT had not been
previously reported in databases. The age of diagnosis of
the patient carrying this variant was 58, and his Gleason
score was 6 (3+3). However, it was difficult to demonstrate
the effect of the ITGA6 variant on the phenotype as the
patient also carried the pathogenic variant MUTYH
c.2T>C. Although novel variants were important because
they cause amino acid changes, their classification became
impossible due to the lack of entries in population databases
and the inability to perform segregation analyzes. For a
better understanding of variants with unknown clinical
significance, it was necessary to obtain allele frequencies
by studying more case groups and to conduct functional
studies.
Variants classified as B/LB due to their high allele
frequencies by ACMG were detected in the genes which
were investigated in our study. B/LB variant was seen in
almost all (17/18) patients who were detected a missense
variant. It has been shown in the literature that benign
variants do not cause disease. Likely benign variants are not
expected to have an effect on the disease, as well. However,
scientific evidence is currently insufficient to conclusively
prove this. Additional evidence is needed to substantiate
this claim. However, the possibility that these variants
may contribute to the disease should not be ignored.
Segregation studies and functional characterization
analyzes are required to confirm the possible effect of these
variants on the disease [19, 20, 21].
This study certainly had some limitations. The first of
these was the low number of cases. The second was the
inclusion of patients over 70 years of age changes the
prevelance of germline mutations. The third was that
the NGS method was not able detect large insertions/
deletions, epigenetic modifications, and copy number
changes from the molecular mechanisms of cancer. The
fourth was that only the probands were tested in this study.
It was necessary to carry out segregation analyzes and
functional studies in order to reveal the disease risk of the
defined variants. Additionally, the absence of mutations
despite a positive family history in some patients included
in the study suggested that there were other genes to be
discovered.
Since the genes sequenced in this study have been
studied together for the first time in PCa in Turkey, novel
and valuable information had been obtained in order
to understand the genetic pathogenesis of the disease,
revealing the frequencies of variants and genotypephenotype relationships. Early detection of pathogenic
variants with germline cancer genetic testing in the clinical
management of PCa patients may improve prognosis and
quality of life in patients in terms of screening family
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members at risk and encouraging pre-metastasis surgery
in the patient. Furthermore, increasing the usability of
germline mutation tests with multigene panels will provide
opportunities for targeted therapies that can improve PCa
patients.
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